Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Leukemia, acute lymphocytic (ALL), child
Stage/Subtype:  untreated childhood acute lymphoblastic leukemia
Country:  U.S.A.
Trial Type:  Treatment
Results 1-19 of 19 for your search:
Start Over
Risk-Directed Therapy in Treating Younger Patients with Newly Diagnosed Acute Lymphoblastic Leukemia
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and under
Trial IDs: TOTXVI, NCI-2011-01254, NCT00549848
Risk-Adapted Chemotherapy in Treating Younger Patients with Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
Status: Active
Phase: Phase III
Type: Supportive care, Treatment
Age: 1 to < 10
Trial IDs: AALL0932, NCI-2011-02599, CDR0000683227, COG-AALL0932, NCT01190930
Combination Chemotherapy in Treating Young Patients with Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 30
Trial IDs: AALL1131, NCI-2011-03797, CDR0000706370, COG-AALL1131, NCT01406756
Combination Chemotherapy with or without Bortezomib in Treating Younger Patients with Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 2 to 30
Trial IDs: AALL1231, NCI-2014-00712, NCT02112916
Immune Response after Stem Cell Transplant in HIV-Positive Patients with Hematologic Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 75 and under
Trial IDs: 2212.00, NCI-2009-01244, 2212, NCT00968630
Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients with Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: Not specified
Trial IDs: 2206.00, NCI-2010-02222, NCT01251575
Combination Chemotherapy and Ofatumumab in Treating Patients with Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Status: Active
Phase: Phase II
Type: Treatment
Age: Not specified
Trial IDs: 2010-0708, NCI-2011-01061, NCT01363128
Gabapentin in Treating Pain Caused by Vincristine Sulfate in Younger Patients with Acute Lymphoblastic Leukemia
Status: Active
Phase: Phase II
Type: Supportive care, Treatment
Age: 1 to 18
Trial IDs: TINALL, NCI-2012-00413, NCT01506453
Donor Progenitor Cell and Natural Kill Cell Transplant in Treating Younger Patients with High-Risk Hematologic Malignancies
Status: Active
Phase: Phase II
Type: Treatment
Age: 21 and under
Trial IDs: HAPNK1, NCI-2013-00609, NCT01807611
Treatment for Advanced B-Cell Lymphoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 3 to 31
Trial IDs: NYMC-157, NCI-2015-01702, L 10,753, NCT01859819
Safety Study of Cord Blood Units for Stem Cell Transplants
Status: Active
Phase: Phase II
Type: Treatment
Age: Any age
Trial IDs: 130116, NCI-2014-01832, 13-H-0116, NCT01861093
Genetically Modified T Cells in Treating Patients With B-Cell Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Status: Active
Phase: Phase I
Type: Treatment
Age: Not specified
Trial IDs: CRETI-NH, NCI-2012-00644, 19384-CRETI-NH, H-19384, NCT00608270, NCT00586391
Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia
Status: Active
Phase: No phase specified
Type: Treatment
Age: 365 days and under
Trial IDs: CDR0000570260, NCI-2014-00665, CCLG-LK-2006-10, DCOG-INTERFANT-06, EUDRACT-2005-004599-19, NCT00550992
Combination Chemotherapy and Rituximab in Treating Younger Patients With B Cell Malignancies
Status: Active
Phase: No phase specified
Type: Treatment
Age: 21 and under
Trial IDs: H-30759, NCI-2013-00985, DA-EPOCH-R, NCT01760226
Partially-Matched Donor Stem Cell Transplant in Treating Younger Patients with High-Risk Hematologic Malignancies
Status: Active
Phase: No phase specified
Type: Treatment
Age: Not specified
Trial IDs: SCT 0813, NCI-2015-00141, CMH 13H11, CMH SCT 0813, SCT 0813 Haplo, NCT02053545
CD34+ Stem Cell Selection in Preventing Graft-Versus-Host Disease in Younger Patients with Malignant Disease Undergoing Donor Stem Cell Transplant
Status: Active
Phase: No phase specified
Type: Treatment
Age: Under 22
Trial IDs: AAAK8060, NCI-2014-00137, NCT02061800
Individualized High Dose Methotrexate in Treating Younger Patients With Cancer and Significant Risk for Side Effects
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 1 to 22
Trial IDs: H-33119, NCI-2014-00923, NCT02076997
Azacitidine and Combination Chemotherapy in Treating Infants with Acute Lymphoblastic Leukemia and MLL Gene Rearrangement
Status: Not yet active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: Under 1
Trial IDs: AALL15P1, NCI-2016-00973, NCT02828358
Start Over